The FDA Came for Peptides. Here's Exactly What Happened.
In early 2023, practitioners who had been prescribing compounded BPC-157, TB-500, and ipamorelin to patients started getting calls from their pharmacies. The compounds were being pulled. The supply chain that had quietly served the functional medicine and longevity space for years was tightening — fast.
What followed was a cascade of regulatory actions, voluntary pharmacy pullbacks, and genuine confusion about what was still legal, what wasn't, and why any of this was happening. Much of the information circulating in the peptide community since then has been incomplete, outdated, or wrong.
Here is a precise account of what actually happened, where things stand now, and what to watch.
The Framework You Need to Understand First
To make sense of what the FDA did, you need to understand the system it operates within.
Compounding pharmacies exist to fill gaps in the pharmaceutical market. Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare medications that aren't commercially available — customized doses for specific patients, prescribed by licensed practitioners.
For years, this framework gave peptides a legitimate clinical pathway. Functional medicine physicians, anti-aging clinics, and longevity practitioners could prescribe compounded BPC-157, ipamorelin, CJC-1295, and others through licensed 503A pharmacies. The legal argument was straightforward: these compounds weren't FDA-approved drugs, they were being prescribed for specific patient needs, and they used bulk drug substances permissible under the compounding framework.
It was a gray zone, but it was a workable one. Patients got access. Practitioners had a defensible legal basis. Pharmacies operated under state and federal licensing that provided accountability.
The question that would eventually disrupt this arrangement was simple: which bulk drug substances are actually permissible?
The 503A Bulks List: Where the Problem Lives
The FDA maintains a list — formally the 503A Bulk Drug Substances List — that governs what raw ingredients compounding pharmacies can use.
There are two relevant categories. Category 1 substances have been evaluated and approved for use in compounding. Category 2 substances have been nominated for review but haven't been evaluated yet. If a substance isn't on either list, compounding pharmacies aren't supposed to use it at all.
For most of the 2010s, enforcement of this framework was inconsistent enough that the peptide supply chain through compounding pharmacies continued largely uninterrupted. Then the FDA started moving.
In 2023, the FDA formalized its position on several key compounds:
BPC-157 landed on the Category 2 list — under review, not approved for compounding. The FDA's stated concern: insufficient human safety and efficacy data. The compound has decades of animal research and widespread use, but no approved human indication and no completed clinical trials in the US.
TB-500 received similar treatment.
For ipamorelin and CJC-1295, the FDA took a different and more aggressive angle: because these compounds were formally investigated as pharmaceuticals (Novo Nordisk and ConjuChem respectively ran clinical trials), the agency argued they are "essentially copies" of investigated drug products. Under this interpretation, they cannot be freely compounded regardless of their status on the bulks list.
The practical effect was immediate. Compounding pharmacies that had been supplying these compounds were put in an untenable position. Continuing to compound BPC-157 or ipamorelin meant potential FDA enforcement action. The risk calculation changed overnight.
What Actually Happened in 2023 and 2024
The regulatory tightening didn't happen as a single announcement. It was a sequence of events.
March 2023: FDA guidance reiterated that bulk drug substances not on the approved 503A list cannot be used in compounding. This wasn't new law — it was a restatement of existing requirements with clearly increased enforcement intent.
Mid-to-late 2023: Several compounding pharmacies began voluntarily pulling peptides in anticipation of enforcement action, even before receiving warning letters. The industry read the direction of travel and responded preemptively. This created a domino effect: as major compounding pharmacies stepped back, the practitioners who relied on them lost their supply relationships.
Concurrent: The International Peptide Society and various physician advocacy groups filed formal comments with the FDA and submitted nominations to add BPC-157 to the Category 1 approved list. The argument was straightforward — the compound has decades of safety data, an established use pattern, and a legitimate medical need that isn't served by any approved alternative.
2024: The FDA continued its review. BPC-157 remained in Category 2 limbo. Some compounding pharmacies continued operating in the space under various legal interpretations; others had fully exited. Access became geographically and institutionally variable in ways that were impossible to predict.
The GLP-1 situation added fuel to the fire. The FDA's aggressive stance on compounded semaglutide and tirzepatide — as the branded versions came off shortage lists — signaled that the agency was in an enforcement posture across the compounded pharmaceutical space broadly, not just for peptides specifically.
The Research Chemical Market Runs Parallel
Throughout all of this, the research chemical market continued operating.
Vendors selling peptides explicitly labeled "for research purposes only, not for human use" occupy a different regulatory space than compounding pharmacies. They are not selling drugs. They are selling research chemicals. The legal exposure sits with the purchaser, not the vendor.
This market is unregulated in the ways that matter for consumer safety. There is no FDA inspection of research chemical labs. There is no USP standard for purity. There is no pharmacist review of what leaves the building.
Third-party testing — HPLC purity analysis, mass spectrometry confirmation of molecular identity — is the only quality assurance mechanism available. Reputable vendors provide certificates of analysis from independent labs. Many vendors do not.
The quality variance in this market is not academic. Peptides that fail purity testing can contain the wrong compound, degradation products, bacterial endotoxins, or simply less of the active ingredient than labeled. For compounds being injected, this matters significantly.
Where Things Stand Now
As of April 2026, the situation remains in flux — and the honest answer is that anyone claiming certainty about the regulatory landscape is overconfident.
BPC-157: Still on Category 2. Not approved for 503A compounding under current guidance. The FDA review is ongoing with no public timeline. Access through compounding pharmacies is severely restricted compared to 2021–2022. The research chemical market remains the primary access route.
Ipamorelin and CJC-1295: The "essentially a copy" argument from the FDA has created significant uncertainty. Some pharmacies continue compounding these under specific legal interpretations; others have stopped. The legal risk has increased materially.
GLP-1 compounds (semaglutide, tirzepatide): A separate but related battleground. The FDA has moved aggressively to restrict compounding as the branded products came off shortage lists, and the legal fight is active. Watch this space — the outcome will set precedent for how aggressively the FDA pursues compounded pharmaceuticals generally.
Selank, Semax, and other nootropic peptides: These compounds have never had a clinical pharmaceutical pathway in the US. They exist entirely in the research chemical category and are unlikely to be affected by the compounding pharmacy restrictions in the same direct way.
What Practitioners Are Actually Doing
The peptide-prescribing medical community has not disappeared. It has adapted.
Some practitioners have moved to international compounding pharmacies — primarily in Canada and Mexico — that operate under different regulatory frameworks. The legal exposure for US patients receiving these compounds from foreign pharmacies is genuinely unclear.
Some practitioners have implemented quality-verified research chemical protocols — accepting the reduced regulatory infrastructure in exchange for continued access, with third-party testing as a quality control substitute.
Some have simply stopped. The legal and professional risk calculus shifted enough that removing these compounds from their protocols was the path of least resistance.
And some are waiting — watching the FDA review, the congressional activity around compounding reform, and the GLP-1 enforcement precedent, before deciding which direction to move.
What to Watch
The 503A Category 2 review for BPC-157. If the FDA moves BPC-157 to Category 1, legitimate clinical access reopens. If it moves to a formal rejection, the compound gets pushed further into the research chemical category. The Peptide Supply will track any movement on this.
Congressional compounding reform. Several pieces of legislation addressing the compounding pharmacy framework have been introduced in recent sessions. The outcomes could meaningfully reshape access — in either direction.
The GLP-1 compounding precedent. How courts and the FDA resolve the semaglutide/tirzepatide compounding fight will signal how aggressive the agency intends to be in the broader compounded pharmaceutical space. Enhanced enforcement of GLP-1 restrictions likely means enhanced scrutiny of peptides.
State-level divergence. Some states have taken independent regulatory positions on compounding. The patchwork of state laws creates complexity but also potential access pathways that vary by location.
The Bigger Picture
What's happening to peptides is a downstream consequence of a tragedy that had nothing to do with them.
In 2012, the New England Compounding Center — a pharmacy in Massachusetts — shipped contaminated steroid injections that caused a fungal meningitis outbreak. Sixty-four people died. The disaster triggered the Drug Quality and Security Act, which dramatically expanded FDA authority over compounding pharmacies and set in motion the regulatory tightening that eventually reached the peptide space.
The safety concern that drove the original regulatory action — bacterial contamination in a poorly-run facility — is not the primary concern with peptides. The compounds themselves have better safety profiles than most approved pharmaceuticals. What they lack is the clinical trial data required to satisfy the FDA's evidentiary standard for human use.
That's the real tension. The FDA's framework is designed to ensure drugs are safe and effective before reaching patients. The peptide research community's position is that the existing evidence — while imperfect — is sufficient to justify clinical access under appropriate physician oversight. These are not obviously incompatible positions. They are positions that require a policy resolution the current framework doesn't provide.
Until that resolution comes — through the 503A review process, through legislation, or through clinical trials that someone eventually decides are worth funding — the access landscape will remain fragmented, uncertain, and dependent on individual practitioners and researchers navigating gray zones that the law has not clearly illuminated.
This article reflects the regulatory situation as of April 2026 and will be updated as the landscape evolves. It is for informational purposes only and does not constitute legal or medical advice.